In the span of five weeks, two of the most anticipated heart drugs in the world did exactly what they were designed to do in the laboratory. One was pelacarsen, tested in the Lp(a)HORIZON trial. The other was ziltivekimab, tested in the ZEUS trial. Neither one reduced heart attacks, strokes, or cardiac deaths.
The first drug lowered lipoprotein(a), the inherited cholesterol particle your doctor may have just started testing for. The second lowered inflammation, the fire everyone agrees drives heart disease. Both hit their targets. Both failed patients where it counts.
If you have ever been told that your heart health comes down to getting one number into range, this should stop you cold. The number is not the root cause. Two massive clinical trials just proved it again, and what they reveal about your own lab results matters far more than what they reveal about the drug companies.
The Pelacarsen Trial: The Number Went Down. The Heart Attacks Did Not.
On September 4, 2026, Novartis announced the top-line results of Lp(a)HORIZON, a phase 3 trial of a drug called pelacarsen. The study enrolled 8,323 people who already had cardiovascular disease and elevated Lp(a), defined as 70 mg/dL or higher. The goal was simple: lower Lp(a) and reduce cardiovascular death, heart attack, stroke, and urgent procedures to open arteries.
Pelacarsen did the first part. Earlier research showed it can cut Lp(a) by up to 80 percent, and Novartis confirmed lower Lp(a) levels were achieved in this trial. But the drug did not meet its primary endpoint. In the words of the company’s own chief medical officer, lower Lp(a) “did not demonstrate that this translated into reduced cardiovascular risk.”
This was supposed to be the trial that launched a new era. Roughly one in five people on Earth carries elevated Lp(a), and several drug companies have spent years racing to build the first approved Lp(a)-lowering therapy. Cardiologists are now openly asking whether Lp(a) is a true cause of disease or a marker that travels alongside it.
A fair word of caution: these are top-line results. The full data, including absolute risk numbers and subgroups, has not yet been presented at a medical meeting. When it is, I will review it. But a drug that lowers its target by that much and still fails to reduce events in more than 8,000 high-risk patients is telling us something important.
ZEUS: The Inflammation Drug That Lowered Inflammation and Nothing Else
Five weeks earlier, on July 31, Novo Nordisk announced results from ZEUS, a trial of more than 6,300 people with cardiovascular disease, chronic kidney disease, and an elevated hs-CRP of 2 mg/L or higher. The drug, ziltivekimab, is an antibody that blocks interleukin-6, one of the body’s master inflammatory signals.
It worked on paper. IL-6 went down. hs-CRP went down. But the rate of cardiovascular death, heart attack, and stroke was essentially identical to placebo, with a hazard ratio of 0.99. That is as close to zero effect as a trial can get. Meanwhile, serious infections were more common in the drug group, which is exactly what you would expect when you shut down part of the immune system.
I have said for years that inflammation is a signal, not a disease. Inflammation is the body responding to something. Block the response without removing the something, and you have silenced the alarm while the house keeps burning.
Why Moving the Number Did Not Move the Outcome
This is not a new story. It is the oldest story in cardiology. Drug companies raised HDL cholesterol with torcetrapib, and more people died. They raised HDL again with niacin on top of a statin in AIM-HIGH, and nothing improved. Now they have lowered Lp(a) and IL-6, and again the heart did not care. Every time medicine treats a lab value as if it were the disease, the patient pays the price.
Here is what the drug model misses. Abnormal labs are warning lights on the dashboard. They sit in the middle of a long biological chain, not at the beginning. Heart disease starts upstream with too much bad stuff and not enough good stuff: ultra-processed food, industrial seed oils, plastics, pesticides, heavy metals, mold, poor sleep, artificial light at night, chronic stress, and loneliness on one side, and missing sunshine, movement, seafood, organ meats, minerals, and real connection on the other.
Those inputs drive oxidative stress, a leaky gut, immune activation, and damage to the endothelium, the delicate lining of your blood vessels. Inflammation and abnormal lipoproteins are what show up on the lab report afterward. Cut the signal with a drug, and the damaging inputs are still there, still working through every other pathway the drug never touched.
Lp(a) fits this pattern perfectly. It is inherited, yes, but it is also the body’s preferred carrier of oxidized phospholipids, and much of its danger appears to come from that oxidized cargo. Oxidized phospholipids on Lp(a) trigger arterial wall inflammation in humans. In other words, the risk from Lp(a) is tied to oxidative stress, and oxidative stress is driven by how you eat, live, and think. Your genes load the gun. Your environment pulls the trigger.
What to Do If Your Lp(a) Is High
First, do not panic. The new 2026 cholesterol guidelines now recommend that every adult have Lp(a) measured at least once, so millions of people are about to learn they carry a high number. A high Lp(a) is a reason to look harder at everything else, not a life sentence and not a reason to reach for the next drug in the pipeline.
Second, understand that Lp(a) is largely set by your genes, and food and lifestyle usually move it only modestly. That is fine. The goal is not to chase the Lp(a) number. The goal is to lower the oxidative stress, inflammation, and endothelial damage that make any lipoprotein dangerous. As I explain in Better Cells. Better Blood Vessels., healthy arteries start with healthy cells. This is where the 100 Year Heart Method does what a single drug cannot.
Eat Well means real, ancestral food. Wild seafood, wild salmon roe, organ meats, grass-finished meat, pasture-raised eggs, organic vegetables, and seasonal fruit. Remove industrial seed oils, refined sugar, and ultra-processed food, because they are among the biggest drivers of lipid oxidation. For many patients, Kickstart My Heart (elk organs) and Wild Salmon Roe are a practical way to get organ and seafood nutrients in their natural matrix, supporting cell membrane health and mitochondrial function.
Live Well means morning sunlight, darkness at night, consistent sleep, daily walking, strength training, clean water, and clean air. It also means hunting down hidden toxin burdens like plastics, heavy metals, and mold in water-damaged buildings.
Think Well means managing chronic stress, building real relationships, and living with purpose. Stress hormones drive blood pressure, blood sugar, and inflammation just as surely as a bad diet does.
If you are currently taking a medication, do not stop or change it on your own. Work with a clinician who will look at the whole picture. And if you have new or worsening chest pain, fainting, or severe shortness of breath, seek emergency care immediately.
Frequently Asked Questions About the Pelacarsen Trial
Lp(a)HORIZON was a phase 3 trial of pelacarsen, a drug designed to lower lipoprotein(a). It enrolled 8,323 people with cardiovascular disease and Lp(a) of 70 mg/dL or higher. On September 4, 2026, Novartis announced that it did not meet its primary goal of reducing cardiovascular death, heart attack, stroke, or urgent artery procedures.
Yes. Earlier research showed pelacarsen can cut Lp(a) by up to 80 percent, and Novartis confirmed lower Lp(a) levels in this trial. The problem is that the lower number did not translate into fewer heart attacks, strokes, or cardiac deaths in the top-line results. Full data has not yet been presented.
ZEUS tested ziltivekimab, an antibody that blocks the inflammatory signal interleukin-6, in more than 6,300 people with cardiovascular disease, kidney disease, and elevated hs-CRP. The drug lowered IL-6 and hs-CRP but did not reduce cardiovascular death, heart attack, or stroke, and serious infections were more common.
Yes. The 2026 cholesterol guidelines recommend that every adult have Lp(a) measured at least once. But a single number tells you little on its own. Test Lp(a) alongside ApoB, oxidized LDL, hs-CRP, homocysteine, and fasting insulin to see what is actually driving your risk.
Lp(a) is largely set by your genes, and food and lifestyle usually move it only modestly. The better goal is to lower the oxidative stress and inflammation that make Lp(a) dangerous, since much of its harm comes from the oxidized phospholipids it carries. That is where the 100 Year Heart Method focuses.
No. Do not stop or change any medication on your own. A high Lp(a) is a reason to look harder at the whole picture with a clinician who will test and interpret your results in context. If you have chest pain, fainting, or severe shortness of breath, seek emergency care.
Test, Don’t Guess
The lesson of these two trials is not that testing is useless. It is that a single number, read in isolation and treated with a single drug, tells you almost nothing about your real risk. Lp(a) matters most in context. At Natural Heart Doctor, we want to know what is happening across the whole chain, including:
- ApoB and Lp(a), to see the full lipoprotein picture
- Oxidized LDL and other oxidative stress markers
- hs-CRP and homocysteine, to measure the fire and one of its fuels
- Fasting insulin and blood sugar markers
- Omega-3 levels, to see whether your cell membranes are getting what they need
Those results tell us where the damage is coming from and what to change first. If your doctor has never checked ApoB, read ApoB: The Cholesterol Test Your Doctor Probably Is Not Ordering. Then we retest to prove the plan is working. Testing without action is wasted money. Action without testing is guesswork. It is why we treat the person, not the number.
Pharmaceutical companies just spent years and billions of dollars proving what root cause cardiology has taught all along. You do not have a pelacarsen deficiency. You do not have an IL-6 blocker deficiency. Your body needs fewer harmful inputs and more of the essential ones.
Stop guessing about your heart. Lp(a) does its damage through oxidized cargo, so measure the oxidation. Order the Oxidative Stress Test Package today at oxidativestresstest.com and find out what is really driving your risk.
Cheers to Your 100 Year Heart,
Dr. Jack Wolfson
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Novartis. Lp(a)HORIZON Phase III topline results for pelacarsen. September 4, 2026.
- TCTMD. Lp(a)HORIZON: Top-line results dash hopes for pelacarsen. September 2026.
- TCTMD. ZEUS trial: ziltivekimab fails to reduce MACE in ASCVD patients. August 2026.
- STAT. A moment of reckoning for preventive cardiology. September 24, 2026.
- Tsimikas S, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020.
- Barter PJ, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007.
- AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011.
- Bergmark C, et al. A novel function of lipoprotein(a) as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008.
- van der Valk FM, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016.
- Family Heart Foundation. 2026 dyslipidemia guidelines.
